542 results on '"Bourlière, M."'
Search Results
2. Efficacy, safety and patient‐reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor‐experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study)
3. Chronic hepatitis C: future treatment
4. Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin
5. Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis: a mediation analysis
6. Impact of common risk factors of fibrosis progression in chronic hepatitis C
7. HEP-08 - Sécurité et tolérance de l’association elbasvir/grazoprévir (EBV/GZR) chez des patients infectés par le VHC : analyse poolée d’essais de phase 2/3
8. Supplement to: Faldaprevir and deleobuvir for HCV genotype 1 infection.
9. Boceprevir and telaprevir: what have we learned?: O123
10. Facteurs socio-comportementaux associés à la mortalité de cause hépatique et non hépatique chez les patients atteints d’hépatite C chronique (cohorte ANRS CO22 HEPATHER)
11. Co-infection avec les hépatites virales
12. Interim analysis of an interferon (INF)- and ribavirin (RBV)-free regimen of daclatasvir (DCV), asunaprevir (ASV), and BMS-791325 in treatment-naive, hepatitis C virus genotype 1-infected patients
13. Hepatitis C therapy in non-genotype 1 patients: the near future
14. Ponction de la surrénale droite sous échoendoscopie : mythe ou réalité ?
15. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial
16. Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV–HCV co-infected patients
17. A national survey of acute hepatitis E in France
18. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection
19. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation
20. Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study
21. Multicentre study of hepatitis B virus genotypes in France: correlation with liver fibrosis and hepatitis B e antigen status
22. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study
23. Slow viral dynamics of hepatitis C virus genotype 4
24. Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder-relapser hepatitis C patients: a prospective multicentre randomized controlled study
25. Lower expression of CD81 B-cell receptor in lymphoproliferative diseases associated with hepatitis C virus infection
26. Serological response to infection with different isolates of hepatitis C virus
27. Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users
28. Résistance aux analogues de nucléosides dans le traitement de l’hépatite chronique B
29. RESISTANCE OF HCV GENOTYPE 4 TO INTERFERON (IFN) ALONE OR TO INTERFERON-RIBAVIRINE
30. EFFICACY AND TOLERABILITY OF HBV VACCINE IN CHRONIC HEPATITIS C PATIENTS (CHC)
31. Dépistage prospectif de la fibrose hépatique à l’aide du Fib-4 calculé automatiquement lors d’un bilan biologique chez 29 707 sujets français
32. Sustained virological response to Do hepatitis C DAA treatments in migrants and non-migrants groups
33. HBV and HIV screening, and hepatitis B immunization programme in the prison of Marseille, France
34. C01/156 IIMPACT OF HGV / GBV-C INFECTION ON PATIENTS WITH CHRONIC HEPATITS C
35. Comment conduire des actes de recherche clinique en milieu libéral: de nombreuses difficultés?
36. Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus‐infected patients with renal impairment: results from a 7‐year, multicentre retrospective cohort study.
37. Indeterminate Second-Generation Hepatitis C Recombinant Immunoblot Test: Detection of Hepatitis C Virus Infection by Polymerase Chain Reaction
38. Hepatitis C Virus Genotypes in Chronic Hepatitis and Response to Interferon-α Therapy
39. Utilisation pratique de l’écho-endoscopic (EUS) pour le suivi quotidien des patients cirrhotiques
40. Efficacy, safety and patient‐reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor‐experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study)
41. Carcinome hépatocellulaire et traitements antiviraux contre le VHB et le VHC
42. SOF/VEL/VOX results in high SVR12 rates when administered for 12 weeks in DAA-experienced patients or for 8 Weeks in DAA-naïve patients: an integrated analysis of the POLARIS-1, POLARIS-2, POLARIS-3 and POLARIS-4 studies
43. Treatment with SOF/VEL or SOF/VEL/VOX is well tolerated and results in high SVR12 in genotype 1–6 HCV infected patients with minimal fibrosis: a retrospective analysis of the ASTRAL and POLARIS clinical studies
44. Treatment and prognosis of acute severe autoimmune hepatitis
45. No impact of RASs on the high efficacy of SOF/VEL/VOX for 12 weeks in DAA-experienced patients: an integrated resistance analysis of the POLARIS-1 and POLARIS-4 studies
46. Efficacy and Safety of IFN Free, Direct-Acting Antiviral-Based Treatment Regimens in Patients with Advanced Liver Disease: Community Treatment of a Real World Population in France
47. Extrahepatic Cancer is the Second Cause of Non Liver-Related Death in Patients with Compensated Viral Cirrhosis and is Associated with Viral Replication (ANRS CO12 CirVir Prospective Cohort)
48. Ledipasvir/Sofosbuvir for 12 or 24 Weeks Is Safe and Effective in Kidney Transplant Recipients with Chronic Genotype 1 or 4 Hcv Infection
49. AVDLIB 2: News Direct-Acting Antiviral (DDA) in HCV Patients with Advanced Liver Disease. Final Results of a the Second Multicenter Prospective Observational Study in Real Life Practice in France
50. Ledipasvir/Sofosbuvir in NS3/4A Protease Inhibitor-Experienced Subjects with HCV Genotype 1 and HIV-Co-Infection Final Results of the ANRS HC31 Softrih Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.